Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer
Pasquale F. Innominato, Sylvie Giacchetti, Thierry Moreau, Georg A. Bjarnason, Rune Smaaland, Christian Focan, Carlo Garufi, Stefano Iacobelli, Marco Tampellini, Salvatore Tumolo, Carlos Carvalho, Abdoulaye Karaboué, Antoine Poncet, David Spiegel and Francis Lévi, for the International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group
Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28072
Circadian-based chemotherapy, which accounts for physiologic oscillations in biologic functions over 24 hours, achieves the best efficacy when good tolerance occurs. The main clinical implication of the current study is that optimization of circadian-based delivery should allow concomitant improvements in the safety and efficacy of chemotherapy with increased benefit for the individual patient.